Clinical trials: Small Cell Carcinoma
Non-small Cell Lung Cancer
Usefulness of Blood Biomarkers for Overall Survival in NSCLC
Lung cancer is the most common cancer type worldwide, with more than 1.1 million annual deaths. There are two types of the disease, namely non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), with the first…
- Trial name
- NCT01936571
- Testing
- Blood samples
- Where
- Netherlands
- Volunteers
- 250 people
- Sponsor
- Maastricht Radiation Oncology
NSCLC Stage IV, ALK Fusion Protein Expression
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
- Trial name
- ARCHER (NCT05950139)
- Testing
- Peptide vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Study Title: Intercalating and maintenance Gefitinib in combination with chemotherapy (gemcitabine plus carboplatin) as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer: A…
- Trial name
- NCT02299765
- Testing
- Gefitinib, gemcitabine, carboplatin
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Sichuan University
Carcinoma，Non-Small-Cell Lung
A Prospective Multi-center Phase III Randomized Controlled Trial
The purpose of this study is to investigate the PFS, ORR, OS and overall toxicity value（OTV）on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.
- Trial name
- NACA (NCT02607592)
- Testing
- cisplatin and pemetrexed, nedaplatin+pemetrexed
- Where
- China
- Volunteers
- 293 people
- Sponsor
- Sun Yat-sen University
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced…
- Trial name
- NCT07688577
- Testing
- XTX501
- Volunteers
- 140 people
- Sponsor
- Xilio Development, Inc.
Carcinoma, Non-Small-Cell Lung
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
This is a study from Eastern Cooperative Thoracic Oncology Project, numbered as ECTOP-1009. Systematically mediastinal lymph node dissection or not in clinical stage T1 ground-glass dominated invasive lung adenocarcinoma: a…
- Trial name
- NCT04527419
- Testing
- No mediastinal lymph node dissection
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion.
- Trial name
- NCT05241028
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hebei Medical University Fourth Hospital
Non Small Cell Lung Cancer
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that has progressed after previous therapy. Safety and response to dasatinib will be assessed.
- Trial name
- TOP0801 (NCT00787267)
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer (NSCLC), Rehabilitation
Rehabilitation With Wearable Monitors for Post-Lung Cancer Surgery
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial evaluating whether a wireless wearable mobile monitoring device combined with a digital rehabilitation program improves pulmonary function at 90…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
- Trial name
- WEAR-LUNG (NCT07733492)
- Testing
- Wireless Wearable Vital Sign and Activity Monitor, Digital Postoperative Rehabilitation Program, Standard Postoperative Rehabilitation Education
- Where
- China
- Volunteers
- 126 people
- Sponsor
- West China Hospital
Lung Cancer, Non Small Cell Lung Carcinoma
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung…
- Trial name
- NCT00111839
- Testing
- Pemetrexed, Matuzumab
- Where
- 58 sites in United States, Austria and 1 more
- Volunteers
- 150 people
- Sponsor
- EMD Serono
Non-small Cell Lung Carcinoma
Hypermetabolism in the Elderly Lung Cancer Patient
Aging and cancer are two conditions associated with extensive metabolic changes that can cause malnutrition. However, the clinical features and the underlying mechanisms leading to malnutrition are different in these two cases.
- Trial name
- HELP (NCT03141957)
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Paris 5 - Rene Descartes
Non-small Cell Lung Cancer
Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether Endostar pumping into vein with Gemcitabine-Cisplatin are more effective than Endostar with Gemcitabine-Cisplatin regularly in the treatment of Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01669707
- Testing
- Endostar -Continued Pumping into+GP, Endostar -injecting into +GP
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chest Hospital
Non-Small Cell Lung Cancer
Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer
Protocol title: Comparison of cost-effectiveness of continuation maintenance therapy with six cycles of pemetrexed versus pemetrexed until disease progression for metastatic non-squamous non-small-cell lung cancer (NSCLC) Study…
- Trial name
- NCT02397239
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- National Cheng-Kung University Hospital
Lung Cancer, Non-small Cell Lung Cancer
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to…
- Trial name
- NCT00721981
- Where
- 8 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Stage III Non-small Cell Lung Cancer, Locally Advanced
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Multinational, randomized, controlled, open-label, multicenter phase II trial. Eligible patients will be randomized in a ratio of 1:1 to Experimental Arm (FDG-PET-based small volume accelerated radiotherapy with concurrent…
- Conditions
- Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
- Trial name
- PACCELIO (NCT06102057)
- Testing
- standard Radiotherapy, Chemotherapy, Immunotherapy
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 110 people
- Sponsor
- TheraOp
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
This randomized phase II trial studies how well pemetrexed disodium with or without crizotinib works in treating patients with stage IV non-small cell lung cancer that has progressed after crizotinib.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT02134912
- Testing
- crizotinib, pemetrexed disodium, laboratory biomarker analysis
- Where
- 167 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003089
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung Cancer
Effect on Patient Reported Outcomes of VATS and SABR (LILAC)
This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with this information the Shared Decision Making…
- Trial name
- LILAC (NCT02882750)
- Testing
- EORTC QLQ-C30 (version 3.0)., PS Q18, Decision Self-Efficacy Scale
- Volunteers
- 244 people
- Sponsor
- University of Leeds
NSCLC, BRAF V600E Mutation
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
- Conditions
- NSCLC, BRAF V600E Mutation, Advanced Cancer, Stage IIIB NSCLC
- Trial name
- NCT05988697
- Testing
- Combind asprin with Trametinib and Dabrafenib
- Volunteers
- 36 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University